Patents Assigned to Ipsen Pharma S.A.S.
  • Publication number: 20130252892
    Abstract: The present invention relates to novel octapeptide compounds of general formula (I), R-AA1-cyclo(AA2-Tyr3-D-Trp4-AA5-Val6-Cys7)-Thr8-NH2??(I) As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.
    Type: Application
    Filed: June 21, 2011
    Publication date: September 26, 2013
    Applicant: IPSEN PHARMA S.A.S
    Inventors: Jean-Christophe Cintrat, Melinda Ligeti, Bernard Rousseau, Franck Artzner, Christophe Tarabout, Marie-Thérèse Paternostre, Nicolas Fay, Roland Cherif-Cheikh, Céline Valery
  • Publication number: 20130210751
    Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of the GHS receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, which is a ligand of the GHS receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of lower than 1000.
    Type: Application
    Filed: March 14, 2011
    Publication date: August 15, 2013
    Applicant: IPSEN Pharma, S.A.S.
    Inventors: Zheng Xin Dong, Jundong Zhang
  • Publication number: 20130157955
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Application
    Filed: April 3, 2012
    Publication date: June 20, 2013
    Applicants: Ipsen Pharma S.A.S., Radius Health, Inc.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • Patent number: 8450266
    Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: May 28, 2013
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Daniel B. DeOliveira
  • Publication number: 20130123170
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: January 4, 2013
    Publication date: May 16, 2013
    Applicant: Ipsen Pharma, S.A.S.
    Inventor: Ipsen Pharma, S.A.S.
  • Patent number: 8440611
    Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34 , that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: May 14, 2013
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
  • Publication number: 20130079282
    Abstract: The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
    Type: Application
    Filed: January 11, 2011
    Publication date: March 28, 2013
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Patent number: 8404804
    Abstract: The present invention relates to methods and intermediates for chemical synthesis of polypeptides and proteins, and more particularly to methods and intermediates for chemically ligating a peptide fragment containing N-terminal N-methyl-cysteine (SEQ ID NO: 1) with another peptide fragment having C-terminal thioester to generate a ?-(methylamino)-thioester intermediate that spontaneously rearranges to form an amide bond. Furthermore, the invention relates to methods of converting N-methyl-thiazolidine to N-methyl-cysteine (SEQ ID NO: 1) of polypeptides and proteins. The invention also relates to methods of synthesizing peptide-thioester from peptide-acid fluoride.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 26, 2013
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, John S. Eynon
  • Publication number: 20130059016
    Abstract: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.
    Type: Application
    Filed: April 29, 2011
    Publication date: March 7, 2013
    Applicant: Ipsen Pharma S.A.S
    Inventors: Béatrice Hacher, Didier Kubiak, Jeremiah Harnett, Nathalie Mondoly
  • Patent number: 8389668
    Abstract: The use of a catalytic ring-opening lactide and glycolide (co)oligomerization system consisting of a strongly acidic ion-exchange resin-type polymeric catalyst and a (co)oligomerization additive, and a lactide and glycolide (co)oligomerization method using said catalytic system, are disclosed.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: March 5, 2013
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Frédéric Ben, Didier Bourissou, Roland Cherif-Cheikh, Anne De Sousa Delgado, Magalie Graullier, Blanca Martin-Vaca
  • Patent number: 8377865
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2 (I) or a pharmaceutically acceptable salt thereof, wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: February 19, 2013
    Assignee: IPSEN Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Publication number: 20130039999
    Abstract: The invention relates to the use of a clay for the preparation of a medicament for treating coeliac disease. Preferably, the clay used is of smectite type.
    Type: Application
    Filed: April 13, 2012
    Publication date: February 14, 2013
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Hélène MATHIEX-FORTUNET
  • Patent number: 8349797
    Abstract: The present invention is directed to a compound according to formula, (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, that act as ligands for one or more of the melanocortin receptors, the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to pharmaceutical compositions useful therefore comprising said peptides.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: January 8, 2013
    Assignee: IPSEN Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Publication number: 20120321714
    Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.
    Type: Application
    Filed: March 26, 2012
    Publication date: December 20, 2012
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Nathalie MONDOLY, Bertrand Poirot, Anne Brochard, Joël Richard, Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Julie Linol, Marie-Noêlle Petit, Barry Victor Llyod Potter, Lok, Wai Lawrence Woo
  • Publication number: 20120316201
    Abstract: The invention relates to novel benzimidazole and imidazopyridine derivatives having the general Formula (I), which have a good affinity with certain subtypes of melanocortin receptors, particularly MC4 receptors. The derivatives are particularly suitable for the treatment of pathological states and diseases involving one or more melanocortin receptors. The invention also relates to pharmaceutical compositions containing said the compounds having the general Formula (I).
    Type: Application
    Filed: June 8, 2012
    Publication date: December 13, 2012
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Lÿdie POITOUT, Valerie Brault, Carole Sackur, Pierre Roubert, Pascale Plas
  • Patent number: 8324386
    Abstract: Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8?-ergolinglmethylthioacetyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH2.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: December 4, 2012
    Assignee: IPSEN Pharma S.A.S.
    Inventors: Michael D. Culler, Zheng Xin Dong, Sun H. Kim, Jacques-Pierre Moreau
  • Publication number: 20120277151
    Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 1, 2012
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Resurreccion ALLOZA MIRAVETE, Roland CHERIF-CHEIKH, Jose-Antonio CORDERO RIGOL, Zheng Xin DONG, Frederic LACOMBE, Maria Dolores TOBALINA MAESTRE
  • Patent number: 8299022
    Abstract: The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: (R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.
    Type: Grant
    Filed: September 24, 2007
    Date of Patent: October 30, 2012
    Assignee: IPSEN Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Publication number: 20120270782
    Abstract: The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof.
    Type: Application
    Filed: November 17, 2010
    Publication date: October 25, 2012
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Enona Gopinath, Susan Park, Tsutomu Arakawa, Joël Richard, Fabio Fais
  • Patent number: 8288560
    Abstract: The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and ? is —NR46R47 or —OR48, R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: October 16, 2012
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Pierre-Etienne Chabrier De Lassauniere, Jeremiah Harnett, Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau